1Wickenden AD. K^+ channels as therapeutic drugtargets [J]. Pharma- cology and therapeutics, 2002, 94: 157.
2Edwards G, Weston AH. Pharmacology of t he potassium channel open- ers [J]. Cardiovasc Drags Ther, 1995, 9: 185.
3Inagaki N, Gonoi T, Clement JP. Reconstitutlon of IK ATP: An in- wardrectifier subunit plus the sulfonylurea receptor [J]. Science, 1995, 270 (5239) : 1166-1170.
3Baranowska M, Koztowska H, Korbut A. Potassium chan- nels in blood vessels: their role in health and disease [J]. Postepy Hig Med Dosw (online), 2007, 61: 596-605.
4Susumu S, Takashi M. Physiological and pathophysiologi- ical roles of ATP-sensitive K+ channels E J ]. Proces in Bio- phy&Mol Biol, 2003, 81: 133-176.
6Jiang K, Yu Z, Shui Q. The pattern of ATP-sensitive K+ channel subunits, Kir6.2 and SUR1 mRNA expressions in DG region is different from those in CA1-3 regions of chronic epilepsy induced bypicrotoxin in rats [J]. Neuro- pathology, 2007, 27(6): 531-538.
7Montalbetti N, Li Q, Timpanaro GA, et al.Cytoskeletal reg- ulation of calcium-permeable cation channels in the hu- man syncytiotrophoblast: role of gelsolin [J]. J Physiol, 2005, 566(2): 309-325.
8Wang H, Long C, Duan Z, et al. A new ATP-sensitive po- tassium channel opener protects endothelial function in cultured aortic endothelial cells [J]. Cardiovasc Res, 2007, 73(3): 497- 503.
